ImmunityBio (IBRX) Change in Acquisitions & Divestments (2015 - 2026)

ImmunityBio (IBRX) has 12 years of Change in Acquisitions & Divestments data on file, last reported at $39.8 million in Q1 2026.

• On a quarterly basis, Change in Acquisitions & Divestments rose 644.82% year-over-year to $39.8 million in Q1 2026; TTM through Mar 2026 was $99.4 million, a 291.47% increase from a year earlier, with the FY2025 full-year figure at $64.9 million, up 208.72% from the prior year.
• Change in Acquisitions & Divestments for Q1 2026 stood at $39.8 million, down from $59.5 million in the prior quarter.
• Over the last five years, Change in Acquisitions & Divestments for IBRX reached as high as $59.5 million in Q4 2025 and fell as low as -$27.0 million in Q3 2024.
• Historically, Change in Acquisitions & Divestments has averaged $13.1 million across 5 years, with a median of $5.4 million in 2025.
• Across the five-year window, Change in Acquisitions & Divestments plunged 100.53% in 2023 and soared 46217.65% in 2024, its largest moves.
• Year by year, Change in Acquisitions & Divestments stood at $56000.0 in 2022, then surged by 17935.71% to $10.1 million in 2023, then sank by 367.33% to -$27.0 million in 2024, then jumped by 320.54% to $59.5 million in 2025, then sank by 33.08% to $39.8 million in 2026.
• Per Business Quant data, the three most recent Change in Acquisitions & Divestments figures were $39.8 million in Q1 2026, $59.5 million in Q4 2025, and $5.4 million in Q1 2025.